Cliby W - Search Results

1

Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.

Basal E, Ayeni T, Zhang Q, Langstraat C, Donahoe PK, Pepin D, Yin X, Leof E, Cliby W. Basal E, et al. Among authors: cliby w. Curr Mol Med. 2016;16(3):222-31. doi: 10.2174/1566524016666160225151131. Curr Mol Med. 2016. PMID: 26917267 Free PMC article.

2

Overexpression of p34cdc2 protein kinase in epithelial ovarian carcinoma.

Barrette BA, Srivatsa PJ, Cliby WA, Keeney GL, Suman VJ, Podratz KC, Roche PC. Barrette BA, et al. Among authors: cliby wa. Mayo Clin Proc. 1997 Oct;72(10):925-9. doi: 10.1016/S0025-6196(11)63362-4. Mayo Clin Proc. 1997. PMID: 9379694

3

Genetic analysis of early- versus late-stage ovarian tumors.

Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Shridhar V, et al. Among authors: cliby w. Cancer Res. 2001 Aug 1;61(15):5895-904. Cancer Res. 2001. PMID: 11479231

4

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI. Hartmann LC, et al. Clin Cancer Res. 2005 Mar 15;11(6):2149-55. doi: 10.1158/1078-0432.CCR-04-1673. Clin Cancer Res. 2005. PMID: 15788660

5

Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.

Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Aletti GD, et al. Gynecol Oncol. 2006 Feb;100(2):283-7. doi: 10.1016/j.ygyno.2005.08.027. Epub 2005 Sep 22. Gynecol Oncol. 2006. PMID: 16182350

6

Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?

Cliby WA, Aletti GD, Wilson TO, Podratz KC. Cliby WA, et al. Gynecol Oncol. 2006 Dec;103(3):797-801. doi: 10.1016/j.ygyno.2006.08.047. Epub 2006 Oct 18. Gynecol Oncol. 2006. PMID: 17052746

7

Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.

Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, Cliby WA. Bakkum-Gamez JN, et al. Gynecol Oncol. 2008 Jan;108(1):141-8. doi: 10.1016/j.ygyno.2007.09.010. Epub 2007 Nov 7. Gynecol Oncol. 2008. PMID: 17988723

8

Random peritoneal biopsies have limited value in staging of apparent early stage epithelial ovarian cancer after thorough exploration.

Powless CA, Bakkum-Gamez JN, Aletti GD, Cliby WA. Powless CA, et al. Gynecol Oncol. 2009 Oct;115(1):86-89. doi: 10.1016/j.ygyno.2009.06.037. Epub 2009 Jul 24. Gynecol Oncol. 2009. PMID: 19631972

9

Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment.

Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, Chi DS, Bristow RE, Cliby WA. Aletti GD, et al. Gynecol Oncol. 2011 Jan;120(1):23-8. doi: 10.1016/j.ygyno.2010.09.010. Epub 2010 Oct 8. Gynecol Oncol. 2011. PMID: 20933255

10

Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.

Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Powless CA, et al. Gynecol Oncol. 2011 Sep;122(3):536-40. doi: 10.1016/j.ygyno.2011.05.001. Epub 2011 Jun 1. Gynecol Oncol. 2011. PMID: 21636114

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters